Repligen (RGEN) Cash & Equivalents (2010 - 2026)

Repligen (RGEN) has reported Cash & Equivalents for 17 consecutive years, with $810.4 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 14.33% year-over-year to $810.4 million; the TTM figure through Jun 2026 stood at $810.4 million (up 14.33% YoY), while the FY2025 annual figure was $767.6 million, up 1.32% from the prior year.
• Cash & Equivalents grew to $810.4 million in Q2 2026 per RGEN's latest filing, from $784.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $810.4 million in Q2 2026 and bottomed at $516.6 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $690.5 million across 5 years, with a median of $728.8 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents dropped 18.77% — and 2024, when it jumped 51.1%.
• Repligen's Cash & Equivalents stood at $523.5 million in 2022, then surged by 43.53% to $751.3 million in 2023, then advanced by 0.84% to $757.6 million in 2024, then increased by 1.32% to $767.6 million in 2025, then increased by 5.58% to $810.4 million in 2026.
• Business Quant data shows RGEN's Cash & Equivalents at $810.4 million in Q2 2026, $784.5 million in Q1 2026, and $767.6 million in Q4 2025.